3-methyl-2-(methylthio)indole | 77564-04-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 3-methyl-2-(methylthio)indole
• 英文别名: 2-Methylthioxy-3-methylindole；3-methyl-2-methylsulfanyl-1H-indole
• CAS: 77564-04-6
• 化学式: C₁₀H₁₁NS
• 分子量: 177.27
• InChiKey: KXKSPFGVKUHIAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.3
• 重原子数：
  12
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.2
• 拓扑面积：
  41.1
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  3-methyl-2-(methylthio)indole 在 manganese(IV) oxide 、 lithium aluminium tetrahydride 、 sodium amide 作用下， 以 乙醚 、 苯 为溶剂， 生成 3-methyl-2-(3-methylbut-2-en-1-yl)-1H-indole
  参考文献：
  名称：

  Baird, Kenneth J.; Grundon, Michael F.; Harrison, David M., Heterocycles, 1981, vol. 15, # 2, p. 713 - 717

  摘要：

  DOI：
• 作为产物：
  描述：

  1,3-二氢-2H-吲哚-2-硫酮 在 sodium tetrahydroborate 、 palladium on activated charcoal 、 sodium carbonate 、 三氯氧磷 作用下， 以 异丙醇 、 丙酮 为溶剂， 反应 6.75h， 生成 3-methyl-2-(methylthio)indole
  参考文献：
  名称：

  Biotransformation of the Brassica Phytoalexin Brassicanal A by the Blackleg Fungus

  摘要：

  The biotransformation of the brassica phytoalexin brassicanal A by the blackleg fungus [Leptosphaeria maculans (Desm.) Ces. et de Not., asexual stage Phoma lingam (Tode ex Fr.) Desm] was investigated. Three main biotransformation products were detected and isolated; their chemical structures were determined by spectroscopic methods and concomitant synthesis. Additionally, the antifungal activities of brassicanal A and its biotransformation products were compared. Overall, the biotransformation pathway suggests that the blackleg fungus has enzymes to carry out this biotransformation different from those involved in the biotransformation of the brassica phytoalexin brassinin.

  DOI：

  10.1021/jf960098u

文献信息

• Preparation of phalloidin and its derivatives
  申请人：Liu Baosheng

  公开号：US20120214968A1

  公开（公告）日：2012-08-23

  The present invention relates to novel phalloidin derivatives and their fluorescent dye conjugates. These new compounds may be used in studies of actin dynamics in living systems. The present invention also relates to methods for preparing such compounds. The synthesis routes combine solid-phase and solution phase peptide synthesis, and has great advantage for efficient preparation of a diverse library of the phalloidin derivatives, especially for the synthesis of phalloidin.

  本发明涉及新型鬼笔环酯衍生物及其荧光染料偶联物。这些新化合物可用于研究活体系统中的肌动蛋白动力学。本发明还涉及制备这类化合物的方法。合成路线结合了固相和溶液相肽合成，对于高效制备多样化的鬼笔环酯衍生物文库具有巨大优势，尤其适用于鬼笔环酯的合成。
• Endothelin antagonistic substance
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0555537A2

  公开（公告）日：1993-08-18

  A peptide derivative of the formula: wherein A is a group of the formula R"O-CO- (wherein R11 is a lower alkyl group or a phenyl group), or a group of the formula R12R13N-C(=O)- (wherein R12 is a lower alkyl group, a cycloalkyl group, a 1-adamantyl group, a phenyl group wherein one or two optional hydrogen atoms on the benzene ring may independently be replaced by a halogen atom, a trifluoromethyl group, a nitro group, an amino group or a formylamino group, a pyridyl group, or a thienyl group, R13 is a hydrogen atom, a lower alkyl group or a cycloalkyl group, or R12 and R13 form, together with the adjacent nitrogen atom, a 5- to 9-membered nitrogen-containing saturated heterocyclic ring having 4 to 8 carbon atoms, wherein among methylene groups forming the ring, one optional methylene group not adjacent to the above nitrogen atom may be replaced by a thio group, and one to four optional hydrogen atoms on the carbon atoms of the heterocyclic ring may independently be replaced by a lower alkyl group, and further two adjacent carbon atoms in the heterocyclic ring may form a benzo-fused ring); B is an oxygen atom or a group of the formula -NR2- (wherein R2 is a hydrogen atom or a lower alkyl group); R3 is a lower alkyl group, a cycloalkyl group, an aryl group, a heterocyclic group, a cycloalkyl lower alkyl group, an aryl lower alkyl group or a heterocyclic lower alkyl group; X1 is an oxygen atom or a group of the formula -NR4- (wherein R4 is a hydrogen atom or a lower alkyl group); R5 is a 3-indolylmethyl, 3-benzothienylmethyl, 1-naphthylmethyl or benzyl group wherein one or two optional hydrogen atoms on the ring may be replaced by a hydroxyl group, a halogen atom, a formyl group, a lower alkyl group, a lower alkoxy group, a lower alkylthio group, a lower alkylsulfinyl group, a lower alkylsulfonyl group, a lower alkoxycarbonyl group, a nitro group or a group of the formula R51-CO-X-2 wherein R51 is a lower alkyl group, a lower alkoxy group, or an amino group which may be substituted by a lower alkyl group, and X2 is an oxygen atom or a group of the formula -NR52- (wherein R52 is a hydrogen atom or a lower alkyl group)}; X3 is an oxygen atom or a sulfur atom; R6 is a hydrogen atom, or a lower alkyl or lower alkenyl group which may have a substituent selected from the group consisting of a hydroxyl group, a lower alkoxy group, a lower alkylthio group and a heterocyclic group; n is 0 or 1; Y is a hydroxymethyl group, a group of the formula CO2R71 (wherein R71 is a hydrogen atom or a lower alkyl group), a group of the formula CONHR72 (wherein R72 is a hydrogen atom or a lower alkyl group which may have a substituent selected from the group consisting of a hydroxyl group, a carboxyl group and a sulfo group), a 1 H-tetrazol-5-yl group, a sulfo group and a phosphono group; or a pharmaceutically acceptable salt thereof.

  式中的肽衍生物： 其中 A 是式 R "O-CO- 的基团（其中 R11 是低级烷基或苯基），或式 R12R13N-C(=O)- 的基团（其中 R12 是低级烷基、环烷基、1-金刚烷基、苯基，其中苯环上的一个或两个任选氢原子可独立地被卤素原子、三氟甲基、硝基、氨基或甲酰氨基、吡啶基或噻吩基取代，R13 是氢原子、低级烷基或环烷基、或 R12 和 R13 与相邻的氮原子一起形成具有 4 至 8 个碳原子的 5 至 9 元含氮饱和杂环，其中在形成环的亚甲基中，不与上述氮原子相邻的一个任选亚甲基可被硫代基团取代，杂环碳原子上的 1 至 4 个任选氢原子可独立地被低级烷基取代，杂环中的另外两个相邻碳原子可形成苯并融合环），R12 和 R13 与相邻的氮原子一起形成具有 4 至 8 个碳原子的 5 至 9 元含氮饱和杂环，其中在形成环的亚甲基中，不与上述氮原子相邻的一个任选亚甲基可被硫代基团取代，杂环碳原子上的 1 至 4 个任选氢原子可独立地被低级烷基取代，杂环中的另外两个相邻碳原子可形成苯并融合环）；B 是氧原子或式-NR2-的基团（其中 R2 是氢原子或低级烷基）； R3 是低级烷基、环烷基、芳基、杂环基、环烷基低级烷基、芳基低级烷基或杂环低级烷基； X1 是氧原子或式-NR4-的基团（其中 R4 是氢原子或低级烷基）；R5是3-吲哚甲基、3-苯并噻吩甲基、1-萘甲基或苄基，其中环上的一个或两个任选氢原子可被羟基、卤素原子、甲酰基、低级烷基、低级烷氧基、低级烷硫基、低级烷基亚磺酰基、低级烷基磺酰基取代、低级烷氧基羰基、硝基或式 R51-CO-X-2 的基团其中 R51 为低级烷基、低级烷氧基或可被低级烷基取代的氨基，X2 为氧原子或式 -NR52- 的基团（其中 R52 为氢原子或低级烷基）}；X3 是氧原子或硫原子；R6 是氢原子，或低级烷基或低级烯基，其取代基可选自由羟基、低级烷氧基、低级烷硫基和杂环基组成的组；n 是 0 或 1；Y 是羟甲基、式 CO2R71 的基团（其中 R71 是氢原子或低级烷基）、式 CONHR72 的基团（其中 R72 是氢原子或低级烷基，其取代基可选自由羟基、羧基和磺基组成的组）、1H-四唑-5-基、磺基和膦基；或其药学上可接受的盐。
• Endothelin antagonists
  申请人：BANYU PHARMACEUTICAL CO., LTD.

  公开号：EP0555537B1

  公开（公告）日：2000-11-02
• BAIRD K. J.; GRUENDON M. F.; HARRISON D. M.; MAGEE M. G., HETEROCYCLES, 1981, 15, NO 2, SPEC. ISSUE, 713-717
  作者：BAIRD K. J.、 GRUENDON M. F.、 HARRISON D. M.、 MAGEE M. G.

  DOI：——

  日期：——
• Phalloidin derivatives and methods for their synthesis
  申请人：Lokey Scott R.

  公开号：US20070275886A1

  公开（公告）日：2007-11-29

  The invention provides a cyclomonomer having actin-binding activity. The cyclomonomer is of utility for the study of the molecular biology of actin polymerization. The cyclomonomer is also useful for the study of and treatment of the toxic effects of Amanita sp. poisoning.